On March 1, Beijing Huafeng Test & Control Technology Co.Ltd(688200) , Dizhe pharmaceutical jointly opened the 2021 performance presentation meeting of the science and innovation board. The core executives made a collective appearance, patiently responded to the concerns of investors, professionally interpreted the highlights of the annual report and actively answered the market hot spots. The two hard technology “pioneers” from the integrated circuit and biomedical industries brought two new, dry and high-value performance presentations to the majority of investors in the form of “offline + online”.
According to the reporter of Shanghai Securities News, in the annual report quarter of 2021, the performance explanation meeting of the science and Innovation Board will continue the principle of full coverage, and encourage the science and innovation board company to hold a comprehensive performance explanation meeting. With the number of Sci-tech Innovation Board companies approaching 400, the lineup for holding the performance briefing will also be further expanded.
“core company ” detailed description of prosperity and commercialization of new drug enterprises “
After Eastroc Beverage (Group) Co.Ltd(605499) opened the first performance presentation meeting in Shanghai stock market on February 28, yesterday Beijing Huafeng Test & Control Technology Co.Ltd(688200) and Dizhe medicine both “took over” and became the first companies to hold the performance presentation meeting of 2021 annual report on the science and innovation board. For a “core company” and a new drug enterprise, the two performance presentations will highlight the industry characteristics and show the style of hard technology, so as to open up a new situation for the follow-up performance presentations.
Beijing Huafeng Test & Control Technology Co.Ltd(688200) is the largest local supplier of semiconductor testing systems in China and one of the few Chinese enterprises that supply semiconductor testing equipment to well-known chip design companies, wafer factories, IDM and packaging and testing manufacturers outside China. Benefiting from the improvement of the prosperity of the semiconductor industry, the company continued to carry out R & D investment and new product development, driving the increase of sales. In 2021, the company achieved an operating revenue of 878 million yuan, a year-on-year increase of 120.96%, a net profit attributable to the parent of 439 million yuan, a year-on-year increase of 120.28%, deducting a net profit not attributable to the parent of 435 million yuan, a year-on-year increase of 193.79%.
The high growth of “core company” is inseparable from the drive of new engine. In 2021, Beijing Huafeng Test & Control Technology Co.Ltd(688200) went deep into R & D and innovation, and its product advantages continued to appear. During the reporting period, the company increased R & D investment and strengthened scientific research and innovation and technical reserves. The annual R & D cost was 94.04 million yuan, a year-on-year increase of 59.03%, accounting for 10.71% of revenue. By the end of the reporting period, the installed capacity of the test system developed and manufactured by the company was 4500, and the installed capacity of products ranked among the top in the world. It is reported that the company’s new product sts8300 has received orders from many high-quality customers and has achieved a certain installed capacity.
In 2022, the prosperity of semiconductor industry has become the most concerned topic of investors. Xu jieshuang, deputy general manager of the company, told investors that the overall direction will always be upward, and the trend and speed of domestic substitution will be further accelerated. Referring to the orders in hand in 2022, Xu jieshuang is optimistic about its stable growth.
Beijing Huafeng Test & Control Technology Co.Ltd(688200) has been listed on the science and innovation board for two years. Investors are also quite concerned about the planning of capital operation such as M & A and expansion. In this regard, Cai Lin, general manager of the company, also admitted that “M & A is the only way for industrial development, and large semiconductor equipment factories in the world come out of this way. We will also learn to think and carefully evaluate. No matter M & A or investment, the most important thing is to focus on the core main business.”
Dizhe pharmaceutical, an innovative drug company just listed in December last year, not only handed over its first annual report after listing on time, but also actively “took the lead” in holding a performance briefing. Different from Beijing Huafeng Test & Control Technology Co.Ltd(688200) , Dizhe pharmaceutical is a non-profit innovative drug company that adopts the fifth set of listing standards of the science and innovation board. The particularity of the company also makes investors have different evaluation criteria and expectations for its value.
In 2021, Dizhe medicine accelerated the development of “new prescriptions”. The R & D investment of the company was 588 million yuan, with a year-on-year increase of 33.7%. While the R & D investment increased steadily, the pipeline of products under research achieved a number of important clinical results. Among them, the oral small molecule targeted drug dzd9008 designed for known mutations in non-small cell lung cancer has preliminarily verified its potential safety and effectiveness in the global phase I / II clinical trial, and has obtained the qualification of “breakthrough therapeutic drug variety” of CDE in China and “breakthrough therapy” of FDA in the United States.
In response to the concerns of investors about the above qualification, Zhang Xiaolin, chairman of the company, explained: “the two qualifications illustrate the recognition of the current clinical trials of the two products by the US FDA and China CDE. After being evaluated, it will help the company strengthen communication with the drug regulatory department, and is expected to shorten the time of market evaluation, which will help our products to be approved as soon as possible after NDA, so as to treat patients and save people.”
Domestic high-quality innovative drugs should not only be listed as soon as possible, but also improve the accessibility of drugs. For innovative drugs in the sprint period of listing, how is the company’s commercialization preparation?
Deputy general manager of the company Wu Qingyi, chief commercial officer, said to investors: “Dzd9008 and other products have carried out clinical trials in many centers around the world. The goal is to be listed in major countries around the world. At present, we are also expanding the possibility of other indications. We are very confident in the current market prospect of the products. In the Chinese market, we will establish an efficient and professional promotion team, and formulate the overall access strategy after the products are listed, including medical insurance negotiation and commercial insurance And other innovative payment possibilities. “
performance description will be fully covered, from “normalization” to “refinement”
Over the past two years since the opening of the science and innovation board, the performance description of the science and innovation company will always maintain a high coverage. According to statistics, the proportion of holding the disclosure period of 2019 annual report and 2020 annual report has reached 70% and 100% respectively. The performance description meeting has become the “standard configuration” of the company. In the annual quarterly report of 2021, the performance description of the science and Innovation Board will further expand its capacity with the growth of the number of companies and realize full coverage again.
The reporter is concerned that after the beneficial exploration in the first two years, the performance description meeting of the science and Innovation Board will gradually move from “normalization” to “refinement”.
First of all, the form of communication is more focused on serving the “sense of experience” and paying more attention to “quality improvement” while “increment”. At present, most Sci-tech Innovation Board companies have accumulated some experience in investor communication and interaction, and are gradually expanding the breadth and depth of communication, improving the interactive effect of performance presentation, and exploring more diversified interactive modes.
For example, Dizhe pharmaceutical chose to hold a live meeting in the trading hall of Shanghai Stock Exchange and conduct webcast simultaneously, so as to unblock the channel of “offline + online” synchronous communication for investors. In addition, multiple forms such as telephone or video access to investors’ questions, playing executive speech videos and visual annual reports also provide investors with a new perspective on the value of the company and effectively enhance investors’ sense of experience and acquisition.
Secondly, the communication content should also focus on the “sense of gain” and “report good news” as well as “report bad news”. The performance statement will be a platform for comprehensively transmitting the company’s value. The company can’t just report good news without reporting bad news. For the uncertainty in the development process and the inherent risks in the operation process of Kechuang board company, it is also necessary to answer questions and dispel doubts for investors in the performance explanation meeting.
From the perspective of investors, it is necessary to maintain the discrimination of companies with governance hidden dangers, financial loopholes and other risks, participate in the performance presentation with problems, make full use of the bridge function of the performance presentation, and truly understand and test the value of the company. At the same time, the participation of various investors, especially professional investors, will also help to improve the effect of the performance briefing. Many companies will also invite a wide range of investors such as CSI small and medium-sized Investor Service Center to attend the meeting to ensure the effective exercise of rights by small and medium-sized shareholders.
